Pathogenesis of and New Therapies for Hepatitis D

被引:80
作者
Koh, Christopher [1 ]
Heller, Theo [1 ]
Glenn, Jeffrey S. [2 ]
机构
[1] NIDDK, Liver Dis Branch, NIH, 10 Ctr Dr,Bldg 10,Room 9B-16,MSC 1800, Bethesda, MD 20892 USA
[2] Stanford Univ, Sch Med, Div Gastroenterol & Hepatol, CCSR Bldg,Room 3115A,269 Campus Dr, Stanford, CA 94305 USA
基金
美国国家卫生研究院;
关键词
HCC Risk; Cancer; Drug Development; Epidemiology; CHRONIC DELTA-HEPATITIS; AMPHIPATHIC DNA POLYMERS; D VIRUS-INFECTION; WESTERN BRAZILIAN AMAZON; CHRONIC LIVER-DISEASE; B SURFACE-ANTIGEN; RISK-FACTORS; ENDEMIC AREA; GENOTYPE-II; HEPATOCELLULAR-CARCINOMA;
D O I
10.1053/j.gastro.2018.09.058
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis delta virus (HDV) infection of humans was first reported in 1977, and now it is now estimated that 15-20 million people are infected worldwide. Infection with HDV can be an acute or chronic process that occurs only in patients with an hepatitis B virus infection. Chronic HDV infection commonly results in the most rapidly progressive form of viral hepatitis; it is the chronic viral infection that is most likely to lead to cirrhosis, and it is associated with an increased risk of hepatocellular carcinoma. HDV infection is the only chronic human hepatitis virus infection without a therapy approved by the US Food and Drug Administration. Peginterferon alfa is the only recommended therapy, but it produces unsatisfactory results. We review therapeutic agents in development, designed to disrupt the HDV life cycle, that might benefit patients with this devastating disease.
引用
收藏
页码:461 / +
页数:17
相关论文
共 150 条
  • [1] Hepatitis D and hepatocellular carcinoma
    Abbas, Zaigham
    Abbas, Minaam
    Abbas, Sarim
    Shazi, Lubna
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (05) : 777 - 786
  • [2] Life cycle and pathogenesis of hepatitis D virus: A review
    Abbas, Zaigham
    Afzal, Rafia
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2013, 5 (12) : 666 - 675
  • [3] Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg plus Chronic Hepatitis B Infection
    Al-Mahtab, Mamun
    Bazinet, Michel
    Vaillant, Andrew
    [J]. PLOS ONE, 2016, 11 (06):
  • [4] AMINI N, 2013, HEPAT MON, V13, pN1071, DOI DOI 10.5812/hepatmon.8210
  • [5] Clinical Features and Seroepidemiology of Anti-HDV Antibody in Patients With Chronic Hepatitis B Virus Infection in Iran: A Meta-Analysis
    Amini, Neda
    Alavian, Seyed Moayed
    Kabir, Ali
    Hosseini, Seyed Yaser Saiedi
    Aalaei-Andabili, Seyed Hossein
    [J]. HEPATITIS MONTHLY, 2011, 11 (12) : 960 - 967
  • [6] Characterization of Hepatitis Delta Virus in Sub-Saharan Africa
    Andernach, Iris E.
    Leiss, Lukas V.
    Tarnagda, Zekiba S.
    Tahita, Marc C.
    Otegbayo, Jesse A.
    Forbi, Joseph C.
    Omilabu, Sunday
    Gouandjika-Vasilache, Ionela
    Komas, Narcisse P.
    Mbah, Okwen P.
    Muller, Claude P.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (05) : 1629 - 1636
  • [7] Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo
    Ank, N
    West, H
    Bartholdy, C
    Eriksson, K
    Thomsen, AR
    Paludan, SR
    [J]. JOURNAL OF VIROLOGY, 2006, 80 (09) : 4501 - 4509
  • [8] ARAGONA M, 1987, LANCET, V1, P478
  • [9] Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition
    Barrera, A
    Guerra, B
    Notvall, L
    Lanford, RE
    [J]. JOURNAL OF VIROLOGY, 2005, 79 (15) : 9786 - 9798
  • [10] SIGNIFICANT REDUCTION OF HBsAg AND HDVRNA BY THE NUCLEIC ACID POLYMER REP 2139 IN CAUCASIAN PATIENTS WITH CHRONIC HBV/HDV CO-INFECTION
    Bazinet, M.
    Pantea, V.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Vaillant, A.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S257 - S258